In this hospital-based prospective study, we aimed to investigate the role of serum YKL-40 at admission in the prediction of one-year clinical outcomes, including poor outcome, all-cause mortality, and recurrent stroke, in patients with AIS. Here, CHI3L1 is linked to stroke disorder.